Upcoming NDA, Potential Partner Add Further Investment Value For Pozen [View article]
1 dollar a pill. but I see your point, I just think there is data to support this product sees decent market acceptance, and with the current market cap and other pipelined products, along with how the company has manuvered things, I see a 300M valuation.
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen [View article]
Insurance companies care about cost. I encourage people to read Obama care thoroughly and the changes upcoming. thanks! Doctors are going to have to get used to doing it the way "they want it."
InVivo Therapeutics: Why Run-Up To March 9 Likely [View article]
after which point, I pointed out to him the conflicting explanation and asked for an explanation for it -- he promptly cancelled my cc with Frank, and never replied again. For me, that is a HUGE RED flag. What should I make of management doing that?
InVivo Therapeutics: Why Run-Up To March 9 Likely [View article]
Furthermore, he told me and one of my team members 2 entirely different explanations on the warrant situation. If this is a legit company, management had better get a fast grip on stuff like yesterday.
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen [View article]
the question is more about cost, and I laid that out clearly. It's about saving on cost, getting at least equal benefit. If the cost is lower than a patient or Doctor combining these 2 on their own, it will gain market acceptance. If it's not, it wont. Article lays out the cost of 1 dollar a day verses 1.16 a day. Pozen's other drug has disappointed because of price point.
InVivo Therapeutics: Why Run-Up To March 9 Likely [View article]
I'm concerned with this one, as when I spoke with management, they told me and another guy I had call them 2 separate things. Furthermore, they guided me Oct - Dec 2012 for human trials, and obviously they missed that. Also, The CEO continues to sell shares. This one smells wrong to me. $NVIV
4 Small Cap Biopharmas With Near-Term Catalysts [View article]
Very astute of you Mike, considering this article came out when POZN was $5.80, and hit $6.38 today. do u mean its a sell because it's near my price target? If so, disregard the above. Have a nice day!
4 Small Cap Biopharmas With Near-Term Catalysts [View article]
And $AEZS has already had a major fail. What happens afterwards in these cases is that any finance deals -- companies lose leverage to negotiate a good deal, and often times end up taking bad deals, sometimes toxic.
InVivo Therapeutics: Why Run-Up To March 9 Likely [View article]
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen [View article]
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen [View article]
InVivo Therapeutics: Why Run-Up To March 9 Likely [View article]
InVivo Therapeutics: Why Run-Up To March 9 Likely [View article]
InVivo Therapeutics: Why Run-Up To March 9 Likely [View article]
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen [View article]
Did you consider this Doctor?
InVivo Therapeutics: Why Run-Up To March 9 Likely [View article]
4 Small Cap Biopharmas With Near-Term Catalysts [View article]
4 Small Cap Biopharmas With Near-Term Catalysts [View article]
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen [View article]
Upcoming NDA, Potential Partner Add Further Investment Value For Pozen [View article]
Loko, sorry to hear you are peeved at $ATRS. I feel as long as they do not get too aggressive with QST, in the long term, they should be ok.
4 Small Cap Biopharmas With Near-Term Catalysts [View article]
4 Small Cap Biopharmas With Near-Term Catalysts [View article]
However, there is more to it, so as I mention, I will need to write on it soon. Have a nice day Adam.
4 Small Cap Biopharmas With Near-Term Catalysts [View article]